• In the second quarter of 2026, American Healthcare REIT, Inc. reported US$39.73 million in sales, US$674.25 million in revenue, US$30.61 million in net income, and US$0.16 in diluted EPS, alongside US$1.72 million of real estate impairment charges, while also raising full‑year 2026 net income guidance to US$108.5 million–US$116.5 million and diluted EPS guidance to US$0.54–US$0.58.
• An interesting shift is that impairment charges fell sharply compared with a year earlier, while net income and earnings per share increased, suggesting that the earnings guidance upgrade is supported by both improved operating results and lower write‑downs on the property portfolio.
• We’ll now examine how the raised full‑year earnings guidance could influence American Healthcare REIT’s previously outlined investment narrative and risk profile.

Find 50 companies with promising cash flow potential yet trading below their fair value.

American Healthcare REIT Investment Narrative Recap

To own American Healthcare REIT, you need to believe in sustained demand for senior housing and healthcare real estate, backed by disciplined capital allocation and stable occupancy. The raised 2026 earnings guidance, supported by higher net income and sharply lower impairment charges, modestly reinforces that near term. However, it does not remove the key risk that performance could cool as occupancies normalize and year over year comparisons become tougher, which may limit how much earnings momentum can support the shares in the short run.

The most relevant announcement here is the updated 2026 earnings guidance to net income of US$108.5 million to US$116.5 million and diluted EPS of US$0.54 to US$0.58. This sits alongside significantly lower real estate impairments of US$1.72 million in the quarter compared with US$12.66 million a year earlier, which helps clarify that the current earnings upgrade is tied both to cleaner property level results and fewer write downs, an important context for investors tracking catalysts such as margin resilience and dividend capacity.

Yet investors should be aware that as occupancy in key segments nears historical norms, leaving less upside from...

American Healthcare REIT's narrative projects $4.0 billion revenue and $252.1 million earnings by 2029.

Uncover how American Healthcare REIT's forecasts yield a $60.07 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range, from about US$60.07 to US$101.85 per share, showing how far opinions can stretch. When you set those views against the recent guidance upgrade and reduced impairments, it underlines why understanding both upside drivers and the risk of slower growth as occupancy stabilizes can materially shape how you think about the stock’s future performance.

Explore 2 other fair value estimates on American Healthcare REIT - why the stock might be worth just $60.07!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your American Healthcare REIT research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free American Healthcare REIT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate American Healthcare REIT's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.